Design and synthesis of substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor α/δ dual agonists

被引:37
|
作者
Kasuga, J
Makishima, M
Hashimoto, Y
Miyachi, H [1 ]
机构
[1] Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan
[2] Nihon Univ, Sch Med, Itabashi Ku, Tokyo 1738610, Japan
基金
日本学术振兴会;
关键词
PPAR; PPAR alpha; PPAR delta; metabolic syndrome;
D O I
10.1016/j.bmcl.2005.10.049
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of phenylpropanoic acids was prepared as candidate dual agonists of peroxisome proliferator-activated receptors (PPAR) alpha and delta. Structure-activity relationship studies indicated that the shape of the linker moiety and the nature of the substituent at the distal benzene ring play key roles in determining the potency and selectivity of PPAR subtype transactivation. Optically active alpha-ethylphenylpropanoic acid derivatives were identified as potent human PPAR alpha and delta dual agonists with potential for the treatment of metabolic syndrome. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:554 / 558
页数:5
相关论文
共 50 条
  • [31] Two Thiophenes Compounds Are Partial Peroxisome Proliferator-Activated Receptor α/γ Dual Agonists
    Zheng, Zhihui
    Yang, Yi
    Shao, Huayi
    Liu, Zongying
    Lu, Xinhua
    Xu, Yanni
    He, Xiaobo
    Jiang, Wei
    Jiang, Qin
    Zhao, Baohua
    Zhang, Hua
    Li, Zhuorong
    Si, Shuyi
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2011, 34 (10) : 1631 - 1634
  • [32] Peroxisome proliferator-activated receptor α/γ dual Agonists for the treatment of type 2 diabetes
    Henke, BR
    JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (17) : 4118 - 4127
  • [33] Indenone derivatives:: A novel template for peroxisome proliferator-activated receptor γ (PPARγ) agonists
    Ahn, Jin Hee
    Shin, Mi Sik
    Jung, Sun Ho
    Kang, Seung Kyu
    Kim, Kwang Rok
    Rhee, Sang Dal
    Jung, Won Hoon
    Yang, Sung Don
    Kim, Seung Jun
    Woo, Joo Rang
    Lee, Jeong Hyung
    Cheon, Hyae Gyeong
    Kim, Sung Soo
    JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (15) : 4781 - 4784
  • [34] Eigenvalue analysis of peroxisome proliferator-activated receptor γ agonists
    Liao, CZ
    Xie, AH
    Shi, LM
    Zhou, JJ
    Lu, XP
    JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 2004, 44 (01): : 230 - 238
  • [35] Peroxisome proliferator-activated receptor (PPAR)γ agonists for diabetes
    Moller, DE
    Greene, DA
    ADVANCES IN PROTEIN CHEMISTRY, VOL 56: DRUG DISCOVERY AND DESIGN, 2001, 56 : 181 - +
  • [36] The Cardiovascular Effects of Peroxisome Proliferator-activated Receptor Agonists
    Kolatkar, Nikheel S.
    AMERICAN JOURNAL OF MEDICINE, 2013, 126 (03): : E11 - E11
  • [37] PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR γ AGONISTS AS NEUROPROTECTIVE AGENTS
    Kaundal, Ravinder K.
    Sharma, Shyam S.
    DRUG NEWS & PERSPECTIVES, 2010, 23 (04) : 241 - 256
  • [38] Therapeutic roles of peroxisome proliferator-activated receptor agonists
    Staels, B
    Fruchart, JC
    DIABETES, 2005, 54 (08) : 2460 - 2470
  • [39] Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists
    Grommes, C
    Landreth, GE
    Heneka, MT
    LANCET ONCOLOGY, 2004, 5 (07): : 419 - 429
  • [40] Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis
    Vosper, H
    Khoudoli, GA
    Graham, TL
    Palmer, CNA
    PHARMACOLOGY & THERAPEUTICS, 2002, 95 (01) : 47 - 62